Cargando…
First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
OBJECTIVE: Prognosis of patients with irresectable cholangiocarcinoma is still poor. The ABC-02 trial established the current first line (1L) standard systemic chemotherapy (CT) with gemcitabine/platinum derivate for advanced cholangiocarcinoma. However, the majority of patients needed therapy adapt...
Autores principales: | Möhring, Christian, Feder, Jan, Mohr, Raphael U., Sadeghlar, Farsaneh, Bartels, Alexandra, Mahn, Robert, Zhou, Taotao, Marinova, Milka, Feldmann, Georg, Brossart, Peter, von Websky, Martin, Matthaei, Hanno, Manekeller, Steffen, Glowka, Tim, Kalff, Jörg C., Weismüller, Tobias J., Strassburg, Christian P., Gonzalez-Carmona, Maria A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631360/ https://www.ncbi.nlm.nih.gov/pubmed/34858809 http://dx.doi.org/10.3389/fonc.2021.717397 |
Ejemplares similares
-
Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature
por: Möhring, Christian, et al.
Publicado: (2023) -
Comparison between regular additional endobiliary radiofrequency ablation and photodynamic therapy in patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy
por: Möhring, Christian, et al.
Publicado: (2023) -
Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy
por: Gonzalez-Carmona, Maria A., et al.
Publicado: (2022) -
Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate
por: Zhou, Taotao, et al.
Publicado: (2022) -
Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report with long term follow-up outcomes
por: Mahn, Robert, et al.
Publicado: (2021)